Experience BIOQUAL Efficiency
Drive Science Forward
Services for Your Preclinical Research Needs
BIOQUAL offers comprehensive in vivo and in vitro preclinical research services to both commercial and government clients. With well-established small and large animal models, our team delivers innovative solutions tailored to your needs. Our extensive in vitro capabilities—including sample processing, serology, and cellular and viral load assays—enable us to provide seamless, high-quality research support from start to finish.
Research Area
BIOQUAL specializes in advancing research across a range of critical scientific areas, with a primary focus on infectious and human diseases. Leveraging extensive expertise in preclinical and translational research, the team supports groundbreaking work in virology, bacteriology, and parasitology. In addition to infectious disease research, BIOQUAL applies its proven methodologies and advanced capabilities to oncology and immunogenicity studies, driving innovation in cancer therapies and immune response characterization.
Animal Models to Fit Your Needs
BIOQUAL offers a wide array of research models to support preclinical studies, including diverse small animal models and non-human primates (NHPs). These models are meticulously developed and maintained to ensure high reliability and relevance to human disease research. Our small animal models encompass various species tailored to specific study needs, while our NHP models provide critical insights into complex biological systems.
Lab Services
BIOQUAL provides a comprehensive range of in vitro services to support diverse preclinical research needs. These include cell-based assays to evaluate proliferation, viability, apoptosis, viral load and immunogenicity testing. High-throughput screening enables rapid compound profiling, while immunoassays such as ELISA, ELISpot, Luminex, Western blot, and flow cytometry deliver detailed analyses of protein expression and immune responses. With tailored toxicology testing and custom assay development, BIOQUAL ensures precise, flexible solutions to advance your research goals.
Additional Services
BIOQUAL provides additional services to support every stage of your research journey, from early R&D to preclinical success. Our advanced BSL3 facilities enable safe and effective research on high-risk pathogens, meeting the highest safety and regulatory standards. Imaging services utilize cutting-edge technologies to deliver critical data on mechanisms of action, therapeutic efficacy, and complex biological interactions. We also offer custom animal model development, ensuring reproducible and translationally relevant models tailored to your study needs. With IND-enabling services, including toxicology, pharmacokinetics, and regulatory documentation, BIOQUAL streamlines your path from bench to clinic, accelerating scientific innovation.
Learn more about the expertise and vision driving our success—meet the team leading BIOQUAL’s innovation.
Join a dynamic team dedicated to advancing science and making a global impact—explore opportunities at BIOQUAL.
BIOQUAL is honored to receive Scientist.com’s 2025 Supplier Recognition Award for outstanding performance in delivering drug discovery research services on its global R&D sourcing platform.
Meet Dr. Hanne Andersen Elyard, BIOQUAL’s new President and Chief Science Officer. In this brief interview, she shares her vision for the company’s future, from expanding scientific capabilities to deepening partnerships across biomedical research.
Advanced Laboratory Capabilities
BIOQUAL’s laboratories are designed to meet the highest safety and quality standards:
Biosafety Levels and Facilities
Our labs operate up to BSL-3 with select agent standards, ensuring the safe handling of highly infectious agents.
State-of-the-Art Technology
From immunoassays to advanced imaging, BIOQUAL’s technology stack supports complex research needs with precision.
Quality and Compliance
We are AAALAC-accredited and can run regulatory-compliant experiments for high-stakes preclinical studies and IND submissions.
